Last reviewed · How we verify
Vincristine Sulfate Liposome Injection plus rituximab
Vincristine Sulfate Liposome Injection plus rituximab is a Small molecule drug developed by Acrotech Biopharma Inc.. It is currently in Phase 1 development. Also known as: Marqibo, VSLI, rituximab, rituxan.
At a glance
| Generic name | Vincristine Sulfate Liposome Injection plus rituximab |
|---|---|
| Also known as | Marqibo, VSLI, rituximab, rituxan |
| Sponsor | Acrotech Biopharma Inc. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
- Constipation
- Nausea
- Fever
- Peripheral Motor Neuropathy
- Peripheral Sensory Neuropathy
- Abdominal Pain
- Conjunctivitis
- Hyperglycemia
- Hypocalcemia
- Hypokalemia
- Hypophosphatemia
- Hypotension
Key clinical trials
- R-CMOP in Patients With Newly Diagnosed Diffuse Large B-cell Lymphoma (PHASE1, PHASE2)
- R-CDOP Combined With Intrathecal Methotrexate for DLBCL Patients With High-risk of CNS Relapse (PHASE2)
- CMOP±R in the Treatment of Untreated Non-Hodgkin's Lymphoma (PHASE2)
- The Efficacy and Safety of the RCMOP Sequential Therapy as a First-line Treatment for Patients With Intermediate-to-high Risk Diffuse Large B-cell Lymphoma Who Had Incomplete Remission. (NA)
- Vincristine Sulfate Liposome Injection (Marqibo®), Bendamustine and Rituximab-Phase I Trial in Indolent B-cell Lymphoma (PHASE1)
- Treatment for Advanced B-Cell Lymphoma (PHASE2)
- Hyper-CVAD With Liposomal Vincristine in Acute Lymphoblastic Leukemia (PHASE2)
- PK Study on Ready-to-Use Injection (VSLI-RTU) 1 Vial & 3 Vial Formulation Marqibo® in Hematological Malignant Patients (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Vincristine Sulfate Liposome Injection plus rituximab CI brief — competitive landscape report
- Vincristine Sulfate Liposome Injection plus rituximab updates RSS · CI watch RSS
- Acrotech Biopharma Inc. portfolio CI
Frequently asked questions about Vincristine Sulfate Liposome Injection plus rituximab
What is Vincristine Sulfate Liposome Injection plus rituximab?
Vincristine Sulfate Liposome Injection plus rituximab is a Small molecule drug developed by Acrotech Biopharma Inc..
Who makes Vincristine Sulfate Liposome Injection plus rituximab?
Vincristine Sulfate Liposome Injection plus rituximab is developed by Acrotech Biopharma Inc. (see full Acrotech Biopharma Inc. pipeline at /company/acrotech-biopharma-inc).
Is Vincristine Sulfate Liposome Injection plus rituximab also known as anything else?
Vincristine Sulfate Liposome Injection plus rituximab is also known as Marqibo, VSLI, rituximab, rituxan.
What development phase is Vincristine Sulfate Liposome Injection plus rituximab in?
Vincristine Sulfate Liposome Injection plus rituximab is in Phase 1.
What are the side effects of Vincristine Sulfate Liposome Injection plus rituximab?
Common side effects of Vincristine Sulfate Liposome Injection plus rituximab include Constipation, Nausea, Fever, Peripheral Motor Neuropathy, Peripheral Sensory Neuropathy, Abdominal Pain.
Related
- Manufacturer: Acrotech Biopharma Inc. — full pipeline
- Also known as: Marqibo, VSLI, rituximab, rituxan
- Compare: Vincristine Sulfate Liposome Injection plus rituximab vs similar drugs
- Pricing: Vincristine Sulfate Liposome Injection plus rituximab cost, discount & access